Anbio Biotechnology (NNNN) Preferred Stock Liabilities (2023 - 2024)
Anbio Biotechnology (NNNN) posted Preferred Stock Liabilities of $4229.0 for Q4 2024, little changed on a QoQ basis from $4229.0 in Q4 2023, and little changed year-over-year from $4229.0 in Q1 2024.
Powered by 
Analysis
Anbio Biotechnology (NNNN) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Anbio Biotechnology has reported Preferred Stock Liabilities for 2 years, with the latest figure at $4229.0 in Q4 2024.
- On a quarterly basis, Preferred Stock Liabilities changed 0.0% year-over-year to $4229.0 in Q4 2024; TTM through Dec 2024 was $4229.0, a 0.0% change from a year earlier, with the FY2024 full-year figure at $4229.0, changed 0.0% from the prior year.
- Preferred Stock Liabilities was $4229.0 for Q4 2024 at Anbio Biotechnology, roughly flat from $4229.0 in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $4229.0 in Q4 2023, with the low at $4229.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 31.10 Bn | 29.22 Bn | 2.18 Bn | - |
| 2 | Lantheus Holdings | 6.59 Bn | 6.00 Bn | 241.86 Mn | - |
| 3 | Heartflow | 4.24 Bn | 3.87 Bn | 53.19 Mn | - |
| 4 | Neogen | 2.58 Bn | 2.39 Bn | 107.80 Mn | - |
| 5 | Butterfly Network | 1.75 Bn | 1.62 Bn | 23.29 Mn | - |
| 6 | QuidelOrtho | 954.15 Mn | 830.75 Mn | - | - |
| 7 | Ceribell | 944.88 Mn | 815.62 Mn | 25.94 Mn | - |
| 8 | Anbio Biotechnology | 941.05 Mn | 929.15 Mn | - | - |
| 9 | Varex Imaging | 780.16 Mn | 694.86 Mn | 76.70 Mn | - |
| 10 | Prenetics Global | 357.49 Mn | 298.35 Mn | 30.20 Mn | - |